Key Highlights

  • Subscription receipts dropped to USD 23.9 million in the third quarter from USD 30.9 million, and to USD 74.6 million over nine months from USD 103.6 million.
  • Fees tied to visits by the affiliated medical group reached USD 23.7 million in the quarter, compared with USD 21.2 million, and USD 77.0 million for nine months, for Amwell (NYSE:AMWL).
  • About 2.7 million virtual visits took place on the platform during the nine months ended September 30, 2026, bringing the lifetime count to roughly 40.3 million.
  • The filing identifies a risk that the Defense Health Agency relationship may not extend beyond the fourth quarter of 2026 on similar financial terms.

Subscription Receipts Fall as Visit Fees Rise

Amwell (NYSE:AMWL) lodged its Form 10-Q for the quarter ended September 30, 2026 on November 3, 2026. Subscription fees received were USD 23.9 million, down from USD 30.9 million in the third quarter of 2025, a decline of about 23% (simple arithmetic). Nine-month receipts fell to USD 74.6 million from USD 103.6 million, about 28% lower. Fees from visits delivered through its affiliated medical group, AMG, went the other way, rising about 12% to USD 23.7 million from USD 21.2 million, and to USD 77.0 million for nine months from USD 70.6 million. The reviewed extract cuts off before the income statement, so total revenue, net loss and cash are not provided here.

How the Platform Monetizes Subscriptions and Visits

Amwell offers its enterprise digital care platform on subscription terms that usually run three years, with longer agreements for its largest strategic partners. A health plan contract typically carries a recurring charge based on members with access, plus add-on program fees, so subscription income follows covered lives and programs. The affiliated medical group, separately, collects fee-for-service payments for each care episode in areas including family medicine, psychiatry, therapy and nutrition. Professional services and Carepoint hardware for hospital and home settings complete the lineup. At December 31, 2025 the company counted about 50 health plans covering more than 90 million lives, plus about 80 large health systems as customers.

Client Concentration, the Defense Health Agency Tie and Other Exposures

The filing discloses a record of losses and the chance that profitability never arrives. It further points to a small number of major clients, sluggish growth and Volatility in digital care, competition from incumbents and newcomers, and slower-than-expected uptake by patients and customers. Management names its capacity to launch and complete strategic transformation initiatives, along with keeping the Defense Health Agency relationship past the fourth quarter of 2026 on comparable terms. Seasonal illness can also make forecasting harder. Because the platform processes personal health information, privacy rules and Cybersecurity Liability create regulatory exposure.

Where Things Stand

Subscription receipts fell about 23% in the third quarter while clinical visit fees from the affiliated medical group rose, and the extract does not state the cause. The part of the filing reviewed omits the revenue, loss and cash totals needed to tell whether this mix shift helps or hurts overall results at Amwell (NYSE:AMWL). The steep subscription decline, the Defense Health Agency relationship, client concentration and the payoff from transformation efforts are the items the filing itself stresses. Investors should look for complete financial statements and comments on contract renewals.